Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1

Inclusion Criteria: * Willing and able to provide informed consent * BMI (Body Mass Index) ≥ 18 kg/m2 * HCV RNA quantifiable at screening and \>1,000 IU/ml * HCV treatment Naïve * HCV genotype 1 * 7\. Confirmation of chronic HCV infection documented by either: A positive anti-HCV antibody test or positive HCV RNA or positive HCV genotyping test at least 6 months prior to the Baseline/Day 1 visit, or A liver biopsy performed prior to the Baseline/Day 1 visit with evidence of chronic HCV infection Exclusion Criteria: * Current or prior history of any of the following: Clinically-significant illness Cirrhosis 2. Screening ECG with clinically significant abnormalities 1. ALT \> 10 x the upper limit of normal (ULN) 2. AST \> 10 x ULN 3. Direct bilirubin \> 1.5 x ULN 4. Platelets \< 150,000/μL 5. HbA1c \> 7.5% 6. Creatinine clearance (CLcr) \< 60 mL /min, as calculated by the Cockcroft-Gault equation 7. Hemoglobin \< 11 g/dL for female subjects; \< 12 g/dL for male subjects. 8. Albumin \< 3.1 g/dL 9. INR \> 1.5 x ULN unless subject has known hemophilia or is stable on an anticoagulant regimen affecting INR 4. Prior exposure to any approved or experimental HCV-specific direct-acting 5\. Pregnant or nursing female or male with pregnant female partner. 6\. Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson's disease, alfa-1 antitrypsin deficiency, cholangitis). 7\. Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV).